Skip to main content
SpringerLink
Log in

Current immunochemotherapy strategies in follicular lymphoma

  • Review
  • Published:
Advances in Therapy Aims and scope Submit manuscript

Abstract

Nowadays, there is no consensus about the best treatment for patients with follicular lymphoma (FL) in differing situations. In frontline treatment, a watchful waiting policy remains a good option if the patient has no risk criteria; the role of rituximab is under investigation in this setting. In patients needing therapy, immunotherapy or immunochemotherapy are the best options; although it has not been established which chemotherapy, including cyclophosphamide, vincristine, and prednisone (CVP); cyclophosphamide, adriamycin, vincristine, and prednisone (CHOP); fludarabine, or bendamustine combinations, is the best partner for rituximab. Following frontline treatment, recent and still unpublished data strongly suggest a role for maintenance with rituximab, instead of observation only. At relapse, immunochemotherapy is the standard induction approach. The role of maintenance after induction is well established, although comparative studies with autologous stem-cell transplantation (ASCT) or other combinations are warranted. The role of ASCT in this setting is a matter of discussion. Other monoclonal antibodies, as well as vaccines and other immunotherapies, are currently under investigation. Finally, allogeneic transplantation should be reserved for a very select group of young high-risk patients in the setting of clinical trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Groves FD, Linet MS, Travis LB, Devesa SS. Cancer surveillance series: non-Hodgkin’s lymphoma incidence by histologic subtype in the United States from 1978 through 1995. J Natl Cancer Inst. 2010;92:1240–1251.

    Article  Google Scholar 

  2. Johnson PW, Rohatiner AZ, Whelan JS, et al. Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. J Clin Oncol. 1995;13:140–147.

    PubMed  CAS  Google Scholar 

  3. Fisher RI, LeBlanc M, Press OW, Maloney DG, Unger JM, Miller TP. New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol. 2005;23:8447–8452.

    Article  PubMed  CAS  Google Scholar 

  4. Liu Q, Fayad L, Cabanillas F, et al. Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center. J Clin Oncol. 2006;24:1582–1589.

    Article  PubMed  Google Scholar 

  5. Hans CP, Weisenburger DD, Vose JM, et al. A significant diffuse component predicts for inferior survival in grade 3 follicular lymphoma, but cytologic subtypes do not predict survival. Blood. 2003;101:2363–2367.

    Article  PubMed  CAS  Google Scholar 

  6. Hiddemann W, Buske C, Dreyling M, Weigert O, Lenz G, Unterhalt M. Current management of follicular lymphomas. Br J Haematol. 2007;136:191–202.

    Article  PubMed  CAS  Google Scholar 

  7. Ott G, Katzenberger T, Lohr A, et al. Cytomorphologic, immunohistochemical, and cytogenetic profiles of follicular lymphoma: 2 types of follicular lymphoma grade 3. Blood. 2002;99:3806–3812.

    Article  PubMed  CAS  Google Scholar 

  8. Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood. 2004;104:1258–1265.

    Article  PubMed  CAS  Google Scholar 

  9. Federico M, Bellei M, Marcheselli L, et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol. 2009;27:4555–4562.

    Article  PubMed  Google Scholar 

  10. Dave SS, Wright G, Tan B, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med. 2004;351:2159–2169.

    Article  PubMed  CAS  Google Scholar 

  11. Ardeshna KM, Smith P, Norton A, et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet. 2003;362:516–522.

    Article  PubMed  CAS  Google Scholar 

  12. Horning SJ, Rosenberg SA. The natural history of initially untreated low-grade non-Hodgkin’s lymphomas. N Engl J Med. 1984;311:1471–1475.

    Article  PubMed  CAS  Google Scholar 

  13. Solal-Celigny P, Lepage E, Brousse N, et al. Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d’Etude des Lymphomes Folliculaires 86 Trial. J Clin Oncol. 1998;16:2332–2338.

    PubMed  CAS  Google Scholar 

  14. Colombat P, Salles G, Brousse N, et al. Rituximab (anti-CD20 monoclonal antibody) as single firstline therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood. 2001;97:101–106.

    Article  PubMed  CAS  Google Scholar 

  15. Colombat P, Brousse N, Morschhauser F, et al. Single treatment with rituximab monotherapy for low-tumor burden follicular lymphoma (FL): survival analyses with extended follow-up (F/Up) of 7 years. Blood. 2006;108:486. Abstract.

    Google Scholar 

  16. McLaughlin P, Grillo-López AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16:2825–2833.

    PubMed  CAS  Google Scholar 

  17. Czuczman MS, Grillo-López AJ, White CA, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol. 1999;17:268–276.

    PubMed  CAS  Google Scholar 

  18. Czuczman MS, Weaver R, Alkuzweny B, et al. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin’s lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol. 2004;22:4711–4716.

    Article  PubMed  CAS  Google Scholar 

  19. Forstpointner R, Dreyling M, Repp R, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2004;104:3064–3071.

    Article  PubMed  CAS  Google Scholar 

  20. van Oers MH, Klasa R, Marcus RE, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood. 2006;108:3295–3301.

    Article  PubMed  CAS  Google Scholar 

  21. Herold M, Haas A, Srock S, et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol. 2007;25:1986–1992.

    Article  PubMed  CAS  Google Scholar 

  22. Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2005;106:3725–3732.

    Article  PubMed  CAS  Google Scholar 

  23. Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood. 2005;105:1417–1423.

    Article  PubMed  CAS  Google Scholar 

  24. Marcus R, Imrie K, Solal-Celigny P, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol. 2008;26:4579–4586.

    Article  PubMed  CAS  Google Scholar 

  25. Salles G, Mounier N, de GS, et al. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELAGOELAMS FL2000 study. Blood. 2008;112:4824–4831.

    Article  PubMed  CAS  Google Scholar 

  26. Rummel MJ, Al Batran SE, Kim SZ, et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin’s lymphoma. J Clin Oncol. 2005;23:3383–3389.

    Article  PubMed  CAS  Google Scholar 

  27. Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: final results of a randomized phase iii study of the StiL (Study Group Indolent Lymphomas, Germany). Blood. 2009;114:405. Abstract.

    Google Scholar 

  28. Rohatiner AZ, Gregory WM, Peterson B, et al. Meta-analysis to evaluate the role of interferon in follicular lymphoma. J Clin Oncol. 2005;23:2215–2223.

    Article  PubMed  CAS  Google Scholar 

  29. Forstpointner R, Unterhalt M, Dreyling M, et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood. 2006;108:4003–4008.

    Article  PubMed  CAS  Google Scholar 

  30. Ghielmini M, Schmitz SF, Cogliatti SB, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood. 2004;103:4416–4423.

    Article  PubMed  CAS  Google Scholar 

  31. Hainsworth JD, Litchy S, Shaffer DW, Lackey VL, Grimaldi M, Greco FA. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin’s lymphoma - a randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol. 2005;23:1088–1095.

    Article  PubMed  CAS  Google Scholar 

  32. Hochster H, Weller E, Gascoyne R, et al. Maintenance rituximab after CVP results in superior clinical outcome in advanced follicular lymphoma (FL): results of the E1496 Phase III Trial from the Eastern Cooperative Oncology Group and the Cancer and Leukemia Group B. Blood. 2009;27:1607–1614.

    CAS  Google Scholar 

  33. van Oers MH, van Glabbeke M, Giurgea M, et al. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin’s lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol. 2010;28:2853–2858.

    Article  PubMed  CAS  Google Scholar 

  34. Salles GA, Seymour JF, Feugier P, et al. Rituximab maintenance for 2 years in patients with untreated high tumor burden follicular lymphoma alter response to immunochemotherapy. J Clin Oncol. 2010;28:15s. Abstract 8004.

    Google Scholar 

  35. Salles GA, Catalano J, Feugier P, et al. Rituximab maintenance for 2 years significantly improves the outcome of patients with untreated high tumor burden follicular lymphoma after response to immunochemotherapy: results of the PRIMA study. Haematologica. 2010;95(suppl. 2):229.

    Google Scholar 

  36. Gea-Banacloche JC. Rituximab-associated infections. Semin Hematol. 2010;47:187–198.

    Article  PubMed  CAS  Google Scholar 

  37. Vidal L, Gafter-Gvili A, Leibovici L, et al. Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and metaanalysis of randomized trials. J Natl Cancer Inst. 2009;101:248–255.

    Article  PubMed  CAS  Google Scholar 

  38. Apostolidis J, Gupta RK, Grenzelias D, et al. High-dose therapy with autologous bone marrow support as consolidation of remission in follicular lymphoma: long-term clinical and molecular follow-up. J Clin Oncol. 2000;18:527–536.

    PubMed  CAS  Google Scholar 

  39. Bierman PJ, Vose JM, Anderson JR, Bishop MR, Kessinger A, Armitage JO. High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin’s lymphoma. J Clin Oncol. 1997;15:445–450.

    PubMed  CAS  Google Scholar 

  40. Freedman AS, Neuberg D, Mauch P, et al. Longterm follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood. 1999;94:3325–3333.

    PubMed  CAS  Google Scholar 

  41. Schouten HC, Qian W, Kvaloy S, et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin’s lymphoma: results from the randomized European CUP trial. J Clin Oncol. 2003;21:3918–3927.

    Article  PubMed  CAS  Google Scholar 

  42. Deconinck E, Foussard C, Milpied N, et al. High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS. Blood. 2005;105:3817–3823.

    Article  PubMed  CAS  Google Scholar 

  43. Gyan E, Foussard C, Bertrand P, et al. High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median followup of 9 years. Blood. 2009;113:995–1001.

    Article  PubMed  CAS  Google Scholar 

  44. Lenz G, Dreyling M, Schiegnitz E, et al. Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group. Blood. 2004;104:2667–2674.

    Article  PubMed  CAS  Google Scholar 

  45. Sebban C, Mounier N, Brousse N, et al. Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d’Etude des Lymphomes de l’Adulte (GELA). Blood. 2006;108:2540–2544.

    Article  PubMed  CAS  Google Scholar 

  46. Ladetto M, De MF, Benedetti F, et al. Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. Blood. 2008;111:4004–4013.

    Article  PubMed  CAS  Google Scholar 

  47. van Besien BK, Loberiza FR Jr., Bajorunaite R, et al. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood. 2003;102:3521–3529.

    Article  PubMed  CAS  Google Scholar 

  48. Morschhauser F, Radford J, Van HA, et al. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol. 2008;26:5156–5164.

    Article  PubMed  CAS  Google Scholar 

  49. Ai WZ, Tibshirani R, Taidi B, et al. Anti-idiotype antibody response after vaccination correlates with better overall survival in follicular lymphoma. Blood. 2009;113:5743–5746.

    Article  PubMed  CAS  Google Scholar 

  50. Freedman A, Neelapu SS, Nichols C, et al. Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma. J Clin Oncol. 2009;27:3036–3043.

    Article  PubMed  CAS  Google Scholar 

  51. Schuster SJ, Neelapu SS, Gause BL, et al. Idiotype vaccine therapy (BiovaxID) in follicular lymphoma in first complete remission: phase III clinical trial results. J Clin Oncol. 2009;27:18.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology, Hospital Clinic, Villarroel 170, 08036, Barcelona, Spain

    Eva Giné, Gonzalo Gutiérrez-García & Armando López-Guillermo

Authors
  1. Eva Giné
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gonzalo Gutiérrez-García
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Armando López-Guillermo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Armando López-Guillermo.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Giné, E., Gutiérrez-García, G. & López-Guillermo, A. Current immunochemotherapy strategies in follicular lymphoma. Adv Therapy 27, 704–713 (2010). https://doi.org/10.1007/s12325-010-0069-7

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12325-010-0069-7

Keywords

Search

Navigation